Retatrutide Research Overview (also known as LY3437943, Triple agonist peptide, GLP-1/GIP/glucagon triple agonist)
A triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, producing the broadest hormonal coverage of any GLP-1 class compound currently in trials. Phase 2 clinical trial data has shown retatrutide to produce the largest weight-loss results documented in metabolic research to date.
What Is Retatrutide?
Retatrutide (LY3437943) is a once-weekly injectable triple agonist of GLP-1, GIP, and glucagon receptors developed by Eli Lilly and currently in Phase 3 clinical trials. It represents the next frontier beyond tirzepatide (dual GLP-1/GIP), adding glucagon receptor agonism that increases energy expenditure and hepatic fat reduction. Phase 2 results show weight losses approaching 25% of body weight at 48 weeks — among the highest ever documented for a pharmacological intervention.
Triple Receptor Mechanism
GLP-1 receptor agonism provides appetite suppression, reduced gastric emptying, and glucose-dependent insulin release. GIP receptor agonism enhances insulin secretion, improves beta cell function, and may reduce GLP-1-associated nausea. Glucagon receptor agonism increases energy expenditure through thermogenesis, drives hepatic fat oxidation (addressing NASH), and — in the context of simultaneous GLP-1 activity — does not produce dangerous hyperglycemia. The three mechanisms are complementary and largely non-overlapping.
Clinical Data
At the highest dose (12mg weekly), retatrutide produced 24.2% mean weight loss at 48 weeks. At lower doses, the compound showed 17–22% weight loss with a favorable safety profile dominated primarily by the expected GI side effects shared with all GLP-1 agonists. Phase 3 trials are ongoing for obesity and T2D.
Quick Reference
| Literature-Reported Dose Range | 0.5–12 mg weekly (dose escalation) |
| Literature-Reported Frequency | Once weekly. Splitting into two smaller weekly doses is an option for better tolerability. |
| Literature-Reported Cycle Length | Continuous therapy |
| Literature-Reported Washout | No cycling required — designed for continuous use; effects reverse on discontinuation |
| Storage | Lyophilized powder at room temperature; reconstituted solution at 2–8°C, use within 28 days |
| Sites Reported in Studies | SubQ — abdomen, thigh, or upper arm; rotate weekly to prevent lipodystrophy |
| Timing | Any time of day; administer same day each week |
Research Indications
Weight Loss
Superior Weight Reduction
Clinical trials demonstrate 17.5% at 24 weeks and 24.2% at 48 weeks - highest recorded for any obesity medication in development
Sustained Weight Management
Continuous weight loss throughout trials with no plateau reached at 48 weeks, suggesting greater long-term potential than current therapies
Triple Mechanism Obesity Treatment
Addresses obesity through appetite suppression, increased energy expenditure, and improved metabolic efficiency via three hormone pathways
Diabetes
Superior Glycemic Control
HbA1c reductions up to 2.16% with 82% of participants achieving target levels below 6.5% - exceeding dual agonist performance
Glucose-Dependent Regulation
Glucose-dependent insulin secretion and glucagon suppression provide balanced glycemic control with minimal hypoglycemia risk
Insulin Sensitivity Enhancement
Marked improvements in insulin sensitivity with potential for significant reduction in exogenous insulin requirements
Cardiovascular
Comprehensive Lipid Improvement
Non-HDL cholesterol reductions up to 26.9%, triglyceride reductions up to 40.6%, and ApoB reductions up to 24.2%
Blood Pressure Optimization
Consistent decreases in both systolic and diastolic blood pressure across clinical trials, supporting cardiovascular risk reduction
Hepatic Fat Reduction
Up to 82% reduction in liver fat with normalization in 90% of participants, addressing MASLD and reducing cardiovascular risk
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Conservative Starting Dose (Weeks 1–4) | 0.5 mg | Once weekly. Splitting into two smaller weekly doses is an option for better tolerability. | SubQ |
| Low-Maintenance (Weeks 5–8) | 1 mg | Once weekly. Splitting into two smaller weekly doses is an option for better tolerability. | SubQ |
| Standard Escalation (Weeks 9–12) | 2 mg | Once weekly. Splitting into two smaller weekly doses is an option for better tolerability. | SubQ |
| Moderate Weight Loss (Weeks 13–18) | 4 mg | Once weekly. Splitting into two smaller weekly doses is an option for better tolerability. | SubQ |
| Advanced Weight Loss (Weeks 19–24) | 8 mg | Once weekly. Splitting into two smaller weekly doses is an option for better tolerability. | SubQ |
| Maximum Efficacy (Week 25+) | 12 mg | Once weekly. Splitting into two smaller weekly doses is an option for better tolerability. | SubQ |
| Type 2 Diabetes — Conservative Start | 2–3 mg | Once weekly. Splitting into two smaller weekly doses is an option for better tolerability. | SubQ |
| Type 2 Diabetes — Maintenance | 3–5 mg | Once weekly. Splitting into two smaller weekly doses is an option for better tolerability. | SubQ |
| Clinical Trial Protocol (Obesity Study) | 1–2 mg (start) | Once weekly. Splitting into two smaller weekly doses is an option for better tolerability. | SubQ |
Timing & Escalation Notes
Dose on the same day each week to maintain hormonal regulation. Can be taken with or without food — injection timing is flexible as long as the weekly interval is consistent. Escalate no faster than every 4 weeks to minimize GI side effects. Continuous therapy — no cycling required. Effects reverse upon discontinuation; restart from a low dose after any break longer than 4 weeks.
Peptide Interactions
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These incretin-based agonists have overlapping pharmacology. Combining them is not supported by combination trials and can make gastrointestinal, hydration, glucose, and adverse-event interpretation difficult; it is not recommended as a routine research combination.
Both cause significant GI effects (gastroparesis, nausea). Retatrutide (triple agonist) and Cagrilintide (amylin agonist) have different mechanisms but compounded GI side effects create substantial risk. Not recommended without specialist supervision.
Both act on the GLP-1 receptor. Combining them stacks effects on the same receptor pathway, increasing risk of severe nausea, gastroparesis, and hypoglycemia. No published safety data exists for this combination at any dose. If using both under clinical supervision, dose reductions and close monitoring are required.
May significantly reduce insulin requirements due to improved glucose control - monitor blood glucose closely and adjust insulin doses accordingly
Safe combination tested in clinical trials with no significant interactions. Both work through different mechanisms to improve glucose control and weight management
Clinical trials included participants on SGLT2 inhibitors with no safety concerns. Complementary mechanisms for glucose control
Space oral contraceptives by 1 hour before retatrutide injection due to delayed gastric emptying effects
Weight loss may affect warfarin requirements - monitor INR more frequently and adjust anticoagulation as needed
Safe combination - different therapeutic targets. BPC-157 promotes tissue repair via growth factors while Retatrutide targets metabolic hormone receptors. BPC-157 may provide GI protective benefits during Retatrutide use.
Safe combination - different cellular systems. Retatrutide targets hormone receptors (GLP-1/GIP/glucagon) while NAD+ supports cellular energy and DNA repair. NAD+ may support metabolic adaptation during weight loss.
Reported Research Timeline
01Week 1–4 (0.5mg) (reported in cited studies): minimal but noticeable appetite suppression, excellent tolerability, early adaptation to triple hormone effects
02Week 4–8 (1mg) (reported in cited studies): moderate appetite control and initial weight loss (2-4%), minimal GI side effects with gradual escalation
03Week 8–12 (2mg) (reported in cited studies): significant appetite suppression and steady weight loss (4-8%), improved glucose control if diabetic
04Week 12–16 (4mg) (reported in cited studies): substantial weight reduction (8-15%) with enhanced energy expenditure and metabolic improvements
05Week 16–20 (8mg) (reported in cited studies): major weight loss milestone (15-20%) with cardiovascular benefits and liver fat reduction
06Week 20+ (12mg) (reported in cited studies): maximum clinical efficacy (20-24.2%) with comprehensive metabolic improvements and sustained benefits
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Most common side effects are gastrointestinal (nausea 43%, diarrhea 33% at 12mg) - typically mild to moderate and dose-dependent
Dysesthesia (abnormal touch sensations) confirmed across two Phase III trials: TRIUMPH-1 (May 2026) reported 5.1% / 12.3% / 12.5% at 4/9/12mg vs. 0.9% placebo, lower than the 8.8-20.9% range first seen in TRIUMPH-4. Reproducible signal suggesting a class-level effect.
Start with 0.5mg weekly and escalate gradually every 4 weeks to minimize gastrointestinal side effects
Phase III discontinuation rates due to adverse events: TRIUMPH-1 at 4.1% / 6.9% / 11.3% (4/9/12mg) vs. 4.9% placebo; TRIUMPH-4 ran higher (12-18%) likely reflecting the older OA population
Monitor for signs of pancreatitis (severe abdominal pain radiating to back) - discontinue immediately if suspected
Not Recommended in patients with personal/family history of medullary thyroid carcinoma or MEN2 syndrome
Seek Medical Attention If:
Severe persistent nausea or vomiting preventing adequate nutrition or hydration
Signs of pancreatitis: severe abdominal pain radiating to back, nausea, vomiting
Symptoms of severe hypoglycemia: confusion, dizziness, sweating, rapid heartbeat
Excessive weight loss (>3 lbs per week consistently or >25% total body weight)
Signs of gallbladder problems: severe right upper abdominal pain, clay-colored stools
Persistent severe diarrhea leading to dehydration or electrolyte imbalances
Quality Indicators
Verified Marker
Pharmaceutical-grade white powder
Lyophilized Retatrutide should appear as a white to off-white powder with uniform texture and no discoloration
Verified Marker
Proper cold chain maintenance
Reconstituted solution requires consistent refrigeration at 2-8°C with temperature monitoring
Verified Marker
Clear reconstituted solution
Properly reconstituted Retatrutide forms a clear, colorless solution without particles, cloudiness, or precipitates
Verified Marker
Stable extended half-life effects
Consistent appetite suppression and metabolic effects between weekly doses indicate proper potency
Acceptable Range
Source verification critical
Due to investigational status and high demand, counterfeit versions circulate - verify pharmaceutical-grade sourcing
Quality Concern
Rapid tolerance or effectiveness loss
Genuine Retatrutide maintains efficacy long-term; rapid tolerance suggests degraded or counterfeit product
Quality Concern
Unusual side effect profile
Effects significantly different from expected GI-predominant profile may indicate contaminated or incorrect product
Research Citations
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea (ADA 86th Scientific Sessions)
Eli Lilly and Company, 2026, Press Release - Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1)
Eli Lilly and Company, 2026, Press Release - Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes (TRANSCEND-T2D-1)
Eli Lilly and Company, 2026, Press Release - Lilly reports first-quarter 2026 financial results, raises full year guidance and highlights momentum of new medicines
Eli Lilly and Company, 2026, Press Release - Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
Giblin K, et al., 2026, Diabetes, Obesity and Metabolism - Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial (TRIUMPH-4)
Eli Lilly and Company, 2025, Press Release - Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial
Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., et al., 2023, New England Journal of Medicine - Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, phase 2 trial conducted in the USA
Rosenstock, J., Frias, J., Jastreboff, A.M., et al., 2023, The Lancet - Efficacy and safety of retatrutide for treatment of people with obesity and metabolic dysfunction-associated steatotic liver disease: a randomised, double-blind, placebo-controlled, phase 2 trial
Sanyal, A.J., Cusi, K., Hartman, M.L., et al., 2024, Nature Medicine - Structural insights into triple agonism at GLP-1R, GIPR and GCGR by retatrutide
Li, W., Xu, Y., Wang, M., et al., 2024, Cell Discovery - LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Coskun, T., Sloop, K.W., Loghin, C., et al., 2022, Cell Metabolism - LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Urva, S., Coskun, T., Loh, M.T., et al., 2023, The Lancet - Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, 2023, N Engl J Med - Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker DJ, 2024, Diabetes Care - Gut hormones and appetite regulation
Hong SH, Choi KM, 2024, Curr Opin Endocrinol Diabetes Obes - Emerging pharmacotherapies for obesity: A systematic review
Kokkorakis M, Chakhtoura M, Rhayem C, 2025, Pharmacol Rev - Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
Giblin K, Kaplan LM, Somers VK, 2026, Diabetes Obes Metab
"
Research Focus
Weight loss, GLP-1/GIP/glucagon triple agonism, Obesity, Type 2 diabetes, NASH
Verified Vendors Carrying Retatrutide
Frequently Asked Questions
What should researchers watch for with Retatrutide?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Retatrutide?
Week 1–4 (0.5mg) (reported in cited studies): minimal but noticeable appetite suppression, excellent tolerability, early adaptation to triple hormone effects
How is Retatrutide typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →